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What’s already known about this topic?101
 Vitiligo is a common skin condition with significant psychological impact.102
 Topical corticosteroids (TCS) are standard care for vitiligo. Narrowband UVB103
(NB-UVB) is only available in secondary care as full-body treatment.104
 Economic evidence for hand-held NB-UVB in combination with topical105
corticosteroid (TCs) is absent.106
What does this study add?107
 Combination treatment, compared to TCS alone, has the lowest incremental108
cost per successful treatment. Whether this is considered cost-effective109
depends on decision makers’ judgement on how much they are willing to pay110
to achieve a successful treatment.111
 Generic utility instruments, such as the EQ-5D-5L, may not be appropriate for112
vitiligo studies due to high ceiling effects. Measurement of quality of life for113
this condition warrants further research.114




Background: Economic evidence for vitiligo treatments is absent.119
Objective: To determine the cost-effectiveness of (a) hand-held narrowband-UVB120
(NB-UVB) and (b) combination of topical corticosteroid (TCS) and NB-UVB121
compared to TCS for localised vitiligo.122
Methods: Cost-effectiveness analysis alongside a pragmatic, 3-arm, placebo-123
controlled RCT with 9 months’ treatment. 517 Adults and children (aged ≥5 years) 124
with active vitiligo affecting <10% of skin recruited from secondary care and125
community were randomised 1:1:1 to receive: TCS; NB-UVB; or both. Cost per126
successful treatment (measured on the Vitiligo Noticeability Scale) was estimated.127
Secondary cost-utility analyses measured QALYs using the EQ-5D-5L for those128
aged 11+ and CHU-9D for those aged 5 to <18.129
Results: Mean (SD) cost per participant was £774.4 (83.71) for NB-UVB, £813.38130
(111.39) for combination treatment and £599.98 (96.18) for TCS. In analyses131
adjusted for age and target patch location, incremental difference in cost for132
combination treatment compared to TCS was £211.46 (95% CI 188.10 to 234.81),133
corresponding to a risk difference of 10.94% (Number-Needed-To-Treat (NNT= 9).134
Incremental cost was £1,932.35 per successful treatment. The incremental135
difference in cost for NB-UVB compared to TCS was £173.44 (95% CI 150.55 to136
196.32) with a risk difference of 5.20% (NNT=19). Incremental cost was £3,335.74137
per successful treatment.138
Conclusion: Combination treatment, compared to TCS alone, has a lower139
incremental cost per additional successful treatment than NB-UVB only. Combination140
treatment would be considered cost effective if decision makers are willing to pay141
£1,932 per additional treatment success.142
143
144




A 2018 systematic review showed that the economic evidence for vitiligo treatment is149
virtually non-existent1. One of two studies identified in this review estimated the150
annual direct cost of treating vitiligo in the USA to be $15,000,000 for the price year151
20042. The other study demonstrated that 32.5% of people with vitiligo would be152
willing to make a one-off payment of €5000 for a cure (2006 price year)3, allowing an153
estimate of the maximum potential for benefit should a “cure” be found. Although154
these papers indicate the cost to an affected person and health care system, they155
do not provide evidence to inform resource allocation decisions. No papers were156
identified that undertook full economic evaluations (those which compare costs and157
benefits of two or more interventions4) of vitiligo treatments alongside clinical trials or158
as economic modelling. This paper reports the first full economic evaluation of159
treatment for localised, non-segmental vitiligo, including current standard treatment160
Topical Corticosteroids (TCS) and new treatment (home-based NB-UVB light161
therapy), alone and in combination with TCS, with the aim of estimating the cost162
effectiveness of these treatments for the UK NHS.163
164
Methods165
This health economic evaluation estimated the within-trial cost-effectiveness of166
i) active hand-held NB-UVB light compared to TCS (standard care) and167
ii) combination of active hand-held NB-UVB plus TCS compared to TCS168
(standard care)169
in terms of cost per additional treatment success (henceforth referred to as treatment170
success) at the end of the treatment period (9 months) for the treatment of limited,171
non-segmental vitiligo, using individual level data collected within the trial. A172
treatment period of 9 months was chosen to reflect clinical practice where clinical173
experience and clinical guidelines suggest that treatment should be initiated for a174
minimum of 3-4 months, but that treatment would normally be required for a longer175
period in order to achieve a clinically meaningful treatment response.176
A secondary objective was to undertake cost utility analyses for those aged 11 and177
over using the EQ-5D-5L and separately for participants aged under 18 years using178
the CHU-9D. Typically, a cost-utility analysis would form the primary analysis as it179
enables decision makers to compare the cost effectiveness of a range of180
interventions for different conditions on a common scale. As utility is measured181
differently in adults and children a common cost-utility analysis was not possible, so182
a clinical outcome was used. Also cost-utility instruments are considered less183
effective at capturing the psychological impact on quality of life, which is considered184
to be more important than physical impacts in vitiligo. A-priori we were also sceptical185
that available generic utility instruments would capture the health-related quality of186
life aspects that people living with vitiligo experience.187
The evaluation was undertaken in line with published guidelines for the economic188
evaluation of health care interventions 4-8. A health economics analysis plan was189
written and approved before the trial database was locked. A full trial report will be190
available through the NIHR Journal series9 and the clinical results paper is available191
in this journal10.192
The trial was conducted in the UK National Health Service (the NHS) - a publicly-193
funded healthcare that is largely free of charge at the point of use. Therefore, the194
analysis was primarily from an NHS perspective, in keeping with the NICE reference195
case8. In a sensitivity analysis, out of pocket costs incurred by participants (or196
parents/guardians) are presented reflecting a personal perspective.197
Resources use and costs198
The primary analysis captured the intervention costs (including any side-effect costs)199
to the NHS and the participant’s wider use of the NHS (including primary care visits;200
secondary care outpatient, inpatient and A&E visits; and prescriptions) as a result of201
vitiligo. Participants’ personal out of pocket expenses (for example, camouflage/202
makeup, sun cream and sun care) incurred from vitiligo were also captured in a203
separate sensitivity analysis taking a broader perspective. Participant time burden for204
home treatment was not costed, but is reported elsewhere 9, 10.205
Resource use for the intervention phase was collected at 3, 6, and 9 months using206
information recorded by participants in daily diaries and collated by the researcher at207
follow-up visits. Intervention and side effect related resource use was recorded in208
Clinical Reports Forms. Further questionnaires collected resource use data at 12,209
15, 18 and 21 months for the follow-up phase.210
Intervention cost was estimated at the individual level. Participants randomised to211
NB-UVB alone were also given a placebo ointment whilst those in the TCS alone212
group received a dummy NB-UVB device. The dummy devices and placebo ointment213
were not costed.214
NB-UVB Device:215
The hand-held device cost was estimated using manufacturer’s purchase price216
divided by an annuity factor (interest rate 3.5%, 5 years) to give an equivalent annual217
cost (EAC). EAC was divided by 12 months and multiplied by 9 to reflect the 9-month218
timeframe. The purchase price of personal protective equipment (goggles and219
glasses) were included at full cost since these are unlikely to be as durable as the220
devices. Costs of quality assurance process for the devices were included. Device221
repair and replacement costs were not included in the analysis faulty devices were222
replaced in the study: though in practice some might be repaired.223
Time spent by investigators training participants on using the device was recorded224
and costed.225
Topical Corticosteroid226
Participants in the TCS intervention group were supplied with two 90g tubes of227
mometasone furoate 0.1% ointment (Elocon® 0.1% Ointment, Merck Sharp &228
Dohme, Hertford). TCS costs were was sourced from the Prescription Cost Analysis229
for 201711 and had the National Average Discount Percentage of 7.37%230
(https://www.nhsbsa.nhs.uk/prescription-data/understanding-our-data/financial-231
forecasting) deducted. The professional pharmacist fee of £1.29 was added,232
assuming that a single tube would be prescribed at any one time. Additional ointment233
requested by participants was recorded and costed.234
Trial participants in all treatment groups were offered appointments with a235
dermatologist at 0, 3, 6, and 9 months, we assumed in the analysis that this would236
happen in routine care . These were costed even though they cancel each other out237
between treatment groups.238
Side effects requiring medical attention from either treatment were recorded as one239
type of unscheduled contact.240
Unit costs were identified from published sources, see Table 1, and valued in241
UK£Sterling 2017. Patient-reported estimates of out of pocket costs resulting from242
vitiligo were captured.243
244
Clinical outcome: Treatment success245
The primary clinical outcome measure in the HI-LIGHT trial was participant-reported246
treatment success, measured at 9 months, using the Vitiligo Noticeability Scale247
(VNS)14. Treatment success, a binary outcome, was defined by whether the248
participant responded that their target vitiligo patch was “a lot less noticeable” or “no249
longer noticeable” in response to the question: "Compared to the start of the study,250
how noticeable is the vitiligo now?". Because no previous studies have compared the251
treatments or outcome used in this study, we used a single study-based estimate of252
effectiveness in the cost-effectiveness analysis.253
Quality of Life254
Quality Adjusted Life Years (QALYs) were estimated in secondary analyses using255
utility scores obtained from the EQ-5D-5L instrument for participants aged 11+256
years18, and the CHU-9D in the analysis focussed on children <18 years.15-17 For257
participants aged 5-6 years old, the CHU-9D was completed by parental proxy. For258
all other ages these instruments were self-completed. We chose to use just one259
version of the EQ-5D-5L in the study for consistency. We chose the CHU-9D for the260
youngest participants because the EQ-5D-Y does not currently have a UK valuation261
set. .262
Utility measurements were collected in clinic at baseline, 9, and 21 months to reflect263
the likely timeframe for observing a clinically meaningful treatment response and in264
order to observe if any response found was sustained longer term.265
In the cost utility analysis, quality of life instrument responses were converted to266
utility scores using the EQ-5D-5L Crosswalk19 UK preference weights in line with267
current recommendations20, 21. The CHU-9D was valued using the UK value set15.268
Following this, the utility values were used to calculate quality adjusted life years269
(QALYs) generated over the trial treatment period of 9 months, using both linear270
interpolation and area under the curve analysis with baseline adjustment24.271
272
Economic analysis273
The economic primary analysis was performed on the full analysis set. In line with274
the primary statistical analysis10, multiple imputation was used to account for missing275
primary outcome data at 9 months. Cost analyses employed multiple imputation with276
chained equations using MI impute in STATA generating 60 (m=60) datasets using277
predictive mean matching and separately by treatment allocation as reported by278
Faria et al23. Given the 9-month time horizon, costs and benefits were not279
discounted.280
Mean (SD) resource use and cost per participant was estimated for each281
randomised group. Mean difference (95% CI) in resource use and cost between282
arms (NB-UVB compared to TCS; and combination treatment compared with TCS) is283
presented.284
Costs and QALYs were adjusted for age and location of target patch as well as285
baseline utility using seemingly unrelated regression (SUR)24.286
Non-parametric bootstrapping was used to determine sampling uncertainty287
surrounding the mean Incremental Cost Effectiveness Ratios (ICERs) by generating288
10,000 estimates of incremental costs and benefits. These estimates were used to289
produce Cost-Effectiveness Acceptability Curves to show the probability each290
intervention arm is cost effective at different values of willingness to pay.291
Other than pre-planned secondary analysis based on the different utility instruments292
used (EQ-5D-5L and CHU-9D), no subgroup analyses were undertaken. The293
secondary outcome for the economic evaluation is quality-adjusted life years294
(QALYs) of participants over 9 months. Mean (SD) utility and mean (SD) QALYs per295
participant per randomised group is estimated, as is mean difference (95% CI) in296
QALYs between arms (NB-UVB to TCS; and combination treatment compared with297
TCS) adjusted for age and location of target patch. In secondary analyses, the298
reported economic analysis used a cost-effectiveness threshold of £20,000 per299
QALY8.300
All analyses were conducted in Stata MP4 version 15.301
Sensitivity analyses were undertaken to explore key uncertainties including (i)302
comparing multiple imputation analysis to a complete case analysis, (ii) varying NB-303
UVB device costs (zero and double the price in the primary analysis), (iii) wider cost304
perspective including vitiligo out-of-pocket costs, (iv) limiting analysis to participants305
with good adherence (defined as greater than 75% adherence), and (v) extending306
the time horizon to 21 months to include the 12 months follow-up period.307
It was expected that the majority of costs and benefits would be captured in the308
treatment period such that a priori it was not considered necessary to develop a309
decision-analytic model for a longer timeframe. This proved appropriate, as quality of310
life scores were similar between treatment arms at 21 months (see supplementary311
Table 6 in the clinical paper10).312
Results313
Baseline characteristics of the participants included in the cost effectiveness analysis314
are described in Table 1 of Thomas et al (submitted)10. With imputation 517315
participants (398 adults, 119 children; 173 TCS, 169 NB-UVB, and 175 Combined316
treatment) were included.317
Intervention costs318
Mean number of devices, googles, glasses, drug costs, dermatology appointments,319
training and unscheduled visit/telephone by group (Table 2) and mean costs (Table320
3) are reported. The mean cost of the intervention per participant for TCS (standard321
care) was £583.42 (SD 29.59), £753.06 (SD 59.16) for NB-UVB, and £792.06 (SD322
94.61) for combination treatment. Details of the time and cost of quality assurance323
processes are shown in Supplementary Table 1.324
Training time was a mean of 73.08 minutes for NB-UVB and 69.17 minutes for325
combination treatment, noting that all participants received both a device and326
ointment (dummy devices and placebo ointment were not costed).327
328
Wider resource use and costs329
Wider health care resource use (primary care, secondary care and medicines) for330
vitiligo beyond those required for the intervention were not significantly different331
between groups (Table 2). Vitiligo patients reported low NHS healthcare usage.332
Table 3 displays mean costs per participant by treatment group using available case333
data. The overall mean cost per participant for NB-UVB was £774.64 (SD 83.71)334
compared to £599.98 (SD 96.18) for TCS - an unadjusted mean difference in cost of335
£174.66 (95% CI 152.75 to 196.66). Combination treatment had overall mean costs336
per participant of £813.38 (SD 111.39); compared to TCS this gave an unadjusted337
mean difference of £213.40 (95% CI 188.33 to 238.46) per participant. These figures338
suggest that the costs of the interventions were not offset by reductions in wider339
healthcare resource use related to vitiligo.340
Primary Economic Analysis341
Cost effectiveness analysis of NB-UVB compared to TCS (standard care)342
The adjusted incremental difference in cost was £173.44 (95% CI 150.55 to 196.32).343
The adjusted risk difference for NB-UVB compared to TCS was 5.20%, this equates344
to a number needed to treat (NNT) of 19; in other words, 19 participants would need345
to be treated for one of them to gain treatment success. The adjusted incremental346
cost was £3,335.74 per additional successful treatment (estimated by dividing the347
adjusted incremental difference in cost, £173.44, by the adjusted risk difference,348
0.052).349
Figure 1a shows the probability that NB-UVB is cost-effective at different possible350
levels of willingness to pay for an additional treatment success; probability increases351
as willingness to pay increases. Figure 1a shows considerable uncertainty352
surrounding the decision as to whether NB-UVB, compared to TCS, represents value353
for money as there is always at least 40% probability of making the wrong decision if354
choosing to fund NV-UVB alone below a threshold value of willingness to pay of355
£10,000 per additional treatment success.356
357
Cost effectiveness analysis of combination treatment compared to TCS358
(standard care)359
The adjusted incremental difference in cost was £211.46 (95% CI 188.10 to 234.81).360
The adjusted risk difference for combination treatment compared to TCS was361
10.94%. This equates to a NNT of 9. The adjusted incremental cost was £1,932.35362
per additional successful treatment.363
Figure 1b shows the probability that combination treatment is cost-effective at364
different possible levels of willingness to pay for an additional treatment success and365
shows that combination treatment is likely to be cost effective if decision makers are366
willing to pay more than £3,000 per additional treatment success as the probability of367
making the wrong decision is less than 50%.368
Sensitivity analyses exploring key uncertainties in the economic evaluation are369
summarised in Supplementary Table 2. Limiting analysis to only adherent370
participants made the most difference to the incremental cost effectiveness ratio371
(£1,836.31 for combination treatment compared to TCS and £3,152.30 for NB-UVB372




248 (55%) trial participants reported having no problems on any of the five domains377
of the EQ-5D-5L at baseline, suggesting that over half of the sample started the378
study in perfect health as defined by EQ-5D-5L. To put this value into perspective, in379
a general population sample from England the number of participants reporting no380
limitations on any dimension of the EQ-5D-5L was 43.87%25. Thus, the ceiling effect381
in this study can be considered large and of an order such as to limit the382
discriminatory power of the instrument for this patient population. Similar levels of383
ceiling effect were observed at subsequent follow-up. Similarly, for the CHU-9D 30%384
of participants aged under 18 years had no problems according to any of the nine385
dimensions on the CHU-9D at baseline. Anxiety and depression on the EQ-5D-5L386
and Worry, tiredness and sleeping on the CHU-9D were the domains for which387
problems were reported most commonly. No floor effect was observed at any time388
point on either instrument. As these high ceiling ratios suggests these instruments389
are unlikely to be able to detect change, we report the mean utility estimates in390
supplementary Tables 3 and 4 and the cost utility analyses in supplementary Table391
5. With this limitation in mind, both NB-UVB and combination treatment compared to392
TCS (standard care) had cost utility ratios within accepted thresholds (<£20,000 per393
QALY) for the sample aged 11 + years (NB-UVB was superior compared to TCS394
than combination treatment in contrast to the cost-effectiveness analysis). Neither395
treatment was cost-effective in the analyses of those participants aged<18 years but396
this may reflect the small sample size (n = 119).397
398
Discussion399
We present the first full economic evaluation of treatments for vitiligo using standard400
care TCS as the comparator. The additional cost of the combination treatment was401
not offset by NHS cost savings but did result in significant treatment success over402
the 9 month treatment period which could be gained if decision makers were willing403
to pay more than the adjusted incremental cost of £1,932.35 per additional404
successful treatment. NB-UVB was less costly than combination treatment but also405
less effective, such that the incremental cost per successful treatment was higher406
than for combination treatment, suggesting that the NHS would get better value for407
money from combination treatment than light therapy alone. There is currently no408
evidence to indicate how much a decision maker would be willing to pay for an409
additional treatment success as defined in this study. Should the decision makers’410
willingness to pay per additional treatment success be low then uncertainty411
surrounding the decision to fund combination treatment is high.412
Treatment options are limited for vitiligo and existing treatments are used little in the413
NHS which may be due to treatments not being offered rather than absence of414
need.26415
Cost effectiveness analysis was undertaken as the primary analysis because it416
enabled us to analyse all participants together, irrespective of age. We had a prior417
belief that generic utility instruments may not fully capture the health-related quality418
of life impairment of people living with vitiligo. This was supported by a high ceiling419
effect on the EQ-5D-5L and CHU-9D at baseline such that there was no capacity to420
measure any gain using these instruments for many participants. The cost utility421
analysis gave different results to the clinical and cost effectiveness results, in that422
NB-UVB appeared more cost effective than combination treatment, compared to423
TCS for those aged 11 and over. There was also a difference in results between the424
cost utility analyses undertaken by age, the new interventions were estimated as425
cost-effective in those aged 11 and over but not in those aged <18 years. This could426
reflect the different utility instrument used but more likely reflects the small sample427
size of the <18 years analysis and the fact that there was a lot of uncertainty around428
the QALYs gained as the gain between groups was very close to zero in all429
comparisons. Therefore, more weight should be attached to the clinical effectiveness430
results and further work to explore the validity of the EQ-5D-5L and CHU-9D in this431
patient group is warranted, given the high ceiling effect observed in this study. It may432
be that a disease specific utility instrument needs to be developed for vitiligo.433
Sensitivity analyses suggested that a wider perspective, cost of the NB-UVB light434
device, and method of dealing with missing data did not change the conclusions435
reached. Incremental cost per treatment success was lowest for those with greatest436
adherence.437
New treatments such as Janus Kinase (JAK) inhibitors are being developed for438
vitiligo and are likely to be costly. The relatively low cost of the interventions439
assessed in this trial may make them affordable when resources are limited. The trial440
has yielded useful cost-effectiveness data which can be used for future comparisons441
with novel treatments.442
A strength of the study was that the HI-Light trial was a large, pragmatic trial of home443
interventions for people with active, limited vitiligo that controlled for common causes444
of bias. Retention throughout the trial was challenging, and the treatments placed445
considerable time burden on participants. Because less than 50% responded to446
secondary outcomes at 21 months, a longer term economic evaluation to 21 months447
was not undertaken, which is a limitation of the present study. However, given448
treatment effects beyond the 9-month period were not sustained one can assume449
that the cost-effectiveness of the interventions would likely decline over time if450
treatments were not continued.451
452
Conclusion453
Combination treatment, compared to TCS alone, has a lower incremental cost per454
successful treatment than NB-UVB but whether this is considered cost-effective will455
depend on how much healthcare decision makers are willing to pay to achieve a456
successful treatment. The fact that vitiligo has few treatment options available, and457
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Figure 1a: Cost effectiveness Acceptability curve for NB-UVB versus TCS Figure 1b: Cost effectiveness Acceptability curve for NB-UVB versus TCS
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Table 1 Unit Costs Table (UK£ sterling, 2017)




Annuity factor 4.515 based on
r = 3.5% and n =
5
Drummond et al.4
Purchase price 149.00 Dermfix Ltd website
Annuitised 9-month purchase pricea 24.75 (Purchase price divided by annuity factor to give
equivalent annual cost (EAC). EAC divided by 12
months and multiplied by 9.)
Annuitised 9-month quality assurance (£17.83
multiplied by annuity factor)
2.96 Quality assurance: Medical Physics, Nottingham
University Hospitals
Glasses (per set) 15.00 Dermfix Ltd website
Goggles (per set) 7.00 Dermfix Ltd website
TCS (per 90g tube of mometasone furoate 0.1%) 12.13 Health and Social Care Information Centre Prescription
Cost Analysis11
Investigator face to face and telephone support (per
minute, assumed band 7 £54 per hour)
0.90 PSSRU 201712
Dermatologist Face to face first appointment
consultant-led
159.00 NHS Schedule of Reference Costs13
Dermatologist Face to face follow-up appointment
consultant-led
129.00 NHS Schedule of Reference Costs13
Dermatologist telephone appointment consultant-led 100.00 NHS Schedule of Reference Costs13
Training time (per minute, assumed band 7 £54 per
hour)
0.90 PSSRU 201712
Primary Care resources (per visit)
GP 37.00 PSSRU 201712
Practice Nurse 10.85 PSSRU 201712
Pharmacist (assumed to be a community pharmacist) 11.11 PSSRU 201712
Hospital Doctor 53.33 PSSRU 201712
Hospital Nurse 15.00 PSSRU 201712
Therapist 27.00 PSSRU 201712
Other (reported by participants) Range from
15.00 to 86.00
PSSRU 201712 and NHS Schedule of Reference
Costs13
Other Resources





Participant and family out of pocket costs Various Estimates reported by participants
Acronyms: NADP = National Average Discount Percentage; NIC = Net Ingredient Costs; TCS = Topical Corticosteroids.
Table 2 Mean (Standard Deviation) resource use according to intervention arm over the 9-month treatment phase for all

















0.00 0.00 (173) 1.08 0.30 (169) 1.083
(1.04 to 1.13)
1.07 0.30 (175) 1.07
(1.03 to 1.12)
Glasses^ 0.00 0.00 (173) 1.41 0.58 (169) 1.41
(1.33 to 1.50)
1.50 0.56 (175) 1.50
(1.41 to 1.58)
Goggles^ 0.00 0.00 (173) 0.46 0.60 (169) 0.46
(0.37 to 0.54)
0.40 0.56 (175) 0.40
(0.32 to 0.48)
TCS 2.15 0.55 (173) 0.00 0.00 (169) -2.15
(-2.23 to -2.07)




0.00 0.00 (173) 73.08 40.47 (169) 73.08
(67.03 to 79.13)





4.00 0.00 (173) 4.00 0.00 (169) 0.00
(0.00 to 0.00)





0.00 0.00 (173) 2.00 0.00 (169) 2.00
(2.00 to 2.00)





0.01 0.11 (173) 0.03 0.20 (169) 0.02
(-0.02 to 0.05)





0.39 0.87 (173) 0.46 0.95 (169) 0.07
(-0.13 to 0.26)





0.02 0.13 (173) 0.04 0.20 (169) 0.02
(-0.01 to 0.06)






0.02 0.17 (173) 0.03 0.20 (169) 0.01
(-0.03 to 0.05)
0.05 0.27 (175) 0.03
(-0.01 to 0.08)
Primary Care and Community
Number 0.12 0.44 (136) 0.17 0.64 (132) 0.06
(-0.07 to 0.19)
0.12 0.55 (142) .002
(-0.12 to 0.12)
Secondary Care
Number 0.48 4.47 (136) 0.20 0.61 (132) -0.28
(-1.05 to 0.49)
0.20 0.63 (142) -0.28
(-1.03 to 0.46)
Other
Medication 0.12 0.50 (138) 0.08 0.35 (133) -0.04
(-0.14 to 0.06)




0.40 1.44 (141) 0.28 0.88 (137) -0.12
(-0.40 to 0.16)
0.31 1.27 (144) -0.09
(-0.41 to 0.23)
* Includes number of NB-UVB devices only.^ participants could choose to have more than one set, for instance if they needed a
parent or partner to help them deliver the treatment.
Table 3 Mean (Standard Deviation) costs and outcomes according to intervention arm over 9-month treatment phase
(UK£Sterling, 2017) for all participants (based on available data)
TCS (Standard
Care) (n=173)














0.00 0.00 (173) 24.75 0.00 (169) 24.75
(24.75 to 24.75)





0.00 0.00 (173) 2.96 0.00 (169) 2.96
(2.96 to 2.96)
2.96 0.00 (175) 2.96
(2.96 to 2.96)
Glasses 0.00 0.00 (173) 21.21 8.74 (169) 21.21
(19.91 to 22.52)
22.46 8.34 (175) 22.46 (21.21 to
23.70)
Goggles 0.00 0.00 (173) 3.19 4.18 (169) 3.19
(2.56 to 3.81)
2.80 3.90 (175) 2.80
(2.22 to 3.38)
TCS 26.08 6.67 (173) 0.00 0.00 (169) -26.08
(-27.09 to -25.07)
25.71 5.99 (175) -0.37
(-1.70 to 0.97)
Training time 0.00 0.00 (173) 65.77 36.42 (169) 65.77
(60.32 to 71.22)





546.00 0.00 (173) 546.00 0.00 (169) 0.00
(0.00 to 0.00)




0.00 0.00 (173) 72.00 0.00 (169) 72.00
(72.00 to 72.00)





0.21 1.93 (173) 0.53 3.64 (169) 0.32
(-0.29 to 0.94)







8.34 17.53 (169) 1.19
(-2.41 to4.79)







5.34 25.78 (169) 3.11
(-1.52 to 7.73)








2.96 20.20 (169) 1.22
(-2.74 to 5.19)






753.06 59.16 (169) 169.64
(159.73 to
179.56)
792.06 94.61 (175) 208.64
(193.82 to 223.46)
Primary Care and Community
Cost 3.90 15.21
(136)
5.90 22.20 (132) 2.00
(-2.56 to 6.57)





9.30 30.05 (132) -1.74
(-15.90 to 12.42)





1.49 7.06 (133) -0.99
(-3.14 to 1.16)


















4.94 20.09 (137) -9.49
(-26.11 to 7.12)










*The number (the percentage) of participants who reported a treatment success (VNS) (a lot less noticeable or no longer
noticeable) at 9 months divided by the number of participants with primary outcome recorded at 9 months. ^ Between group
difference is number of participants experiencing a treatment success (between group risk difference %).


















testing 10 0.52 5 2.58 3.10
Output testing 20 1.03 8 4.13 5.17
Spectral
characterisation 30 1.55 10 5.17 6.72
Data













Output testing 20 1.03 8 4.13 5.17
Data
administration 5 2.58 2.58
The quality assurance process involved device in and device out processes. Before
devices were issued to participants they were tested for electrical safety and output,
spectral characterisation was undertaken, and some data administration was
involved. When devices were returned, they again had their output tested and some
data administration was involved. Supplementary table 1 shows the time and cost for
each aspect, estimated using the expert opinion of staff based in Medical Physics at
the Queen’s Medical Centre. Staff time was assumed to be a mid-point band 5 on
Agenda for Change and the batch size was assumed to be 10 devices at once.
Quality assurance costs were also multiplied by the annuity factor to gain the cost
over the study period. In reality, quality assurance might be undertaken more
frequently than every 5 years or may be provided using a different service model
(e.g. specialist versus local sites undertaking the activity) which may affect cost but
the impact of this assumption is tested in the sensitivity analysis section, where price
is varied to see the impact on cost per treatment success.
Supplementary Table 2: Summary of sensitivity analyses (adjusted results)


























£173.44 5.20% £3,335.74 £211.46 10.94% £1,932.35
Complete
case

















£193.34 13.87% £1,393.98 £230.83 20.06% £1,150.65
Complete case analysis
The primary analysis assumed data to be missing at random and undertook
imputation to allow for this23. Supplementary Table presents the results for a
complete case analysis, which only includes participants with complete resource use
and outcome data in order to see if this changes the conclusions reached in the
primary analysis. Three hundred and forty eight participants had complete data on
both cost and outcome (success of treatment) – 113 in TCS only, 115 in NB-UVB
only and 120 in combination treatment.
The cost of the NB-UVB device
There is uncertainty about how the device would be prescribed and used within the
NHS. If adopted as an effective treatment, patients may have to pay for the device
themselves (with training, support and quality assurance paid for by the NHS), or the
device might be adopted and provided free at point of use by the NHS for NHS
patients. The primary analysis annuitised the device cost, assuming that the device
would be used for a period of 5 years, but there is uncertainty surrounding this period
of use and in practice it may be that the devices are not returned by patients at the
end of treatment. We re-estimated the incremental cost per successful treatment
assuming that patients paid for the device, quality assurance, glasses and goggles
as one extreme and at the other we doubled the price of the device, quality
assurance, goggles and glasses to provide an upper estimate.
Wider cost perspective
As part of the trial, participants were asked about the out of pocket costs (if any)
incurred by themselves or their families as a result of their vitiligo. These costs were
added to the primary analysis results (NHS perspective only) to see how they would
impact on the incremental cost per treatment success. Forty-seven (11.1%) of
participants reported incurring out of pocket costs during the 9-month treatment
period: 17 in TCS only, 17 in NB-UVB only and 13 in the combination group. The
mean number of items and mean cost per participant by group can be seen in Table
2 and Table 3 in the main paper. The type of items included (from most to least
purchased), camouflage / makeup, sun cream and sun care, clothes/scarves, face
creams / moisturisers / emollients, fake tan / tanning products, travel for
appointments, private appointment including multivitamins, and herbal remedies.
Taking into account the participant out of pocket costs in relation to vitiligo reduced
the incremental cost per treatment success, as these costs were higher in the
standard care arm (TCS only) (Supplementary table 2 for estimates).
Impact of Adherence
Since significant clinical effectiveness was found and a little under half of the
participants used the treatment for over 75% of the expected duration, the primary
economic analysis was repeated including only the adherent sample, where
adherence was estimated as total sessions used divided by total expected sessions.
227 participants adhered to treatments >75% of the time; this sample was used as
the adherent sample, minus 3 participants (1 of whom had the primary outcome
missing and 2 whom had cost data missing). The intervention was more cost-
effective for patients who adhered to treatment, as they were the ones most likely to
achieve a successful outcome (See Supplementary table 2 for estimates).
Longer term analysis (21 months)
In the health economics analysis plan we intended to repeat the analysis over a 21
month timeframe to see if value for money was sustained. However, in the trial, only
30.4% of participants had complete data on NHS resource use in months 10-21,
44.5% of participants aged 11+ completed the EQ-5D -5L at 21 months, and 43.3%
of participants aged <18 had completed the CHU-9D at 21 months. Given the
sparsity of data an economic evaluation over the longer-term follow up was not
conducted. Mean estimates of the participant’s (all ages, n=517) wider NHS use over
months 10 to 21 (the follow-up period) and utility at 21 months were estimated. Only
157 participants had complete resource use data for the whole 12 month follow-up
period (which may have been for zero use), 64 had nine months of data available, 56
had six months of data available, 59 had three months worth of data available and
181 had no resource use data recorded for the follow-up period. The mean
quarterly NHS cost per participant over the 12 month follow-up period was £21.26
(sd 46.32) for combination treatment (n=114), £25.89 (sd 52.82) for NB-UVB alone
(n=117), and £21.74 (sd 42.33) for TCS alone (n=105). The mean prescription cost
per participant over the 12 month follow-up period was £14.82 (sd 45.22) for
combination treatment (n=114), £13.78 (sd 45.63) for NB-UVB alone (n=117), and
£13.20 (sd 51.44) for TCS alone (n=107). The mean out of pocket cost per
participant over the 12 month follow-up period was £42.85 (sd 398.74) for
combination treatment (n=114), £3.62 (sd 16.93) for NB-UVB (n=117), and £8.48 (sd
39.41) for TCS (n=107).
Mean utility (EQ-5D-5L) per participant aged 11+ at 21 months was 0.856 (sd 0.230)
for combination treatment (n=73), 0.865 (sd 0.231) for NB-UVB (n=61), and 0.833
(sd 0.274) for TCS (n=69). Mean utility (CHU-9D) per participant (aged <18 years) at
21 months was 0.938 (sd 0.054) for combination treatment (n=20), 0.941 (sd 0.056)
for NB-UVB (n=16), and 0.937 (sd 0.118) for TCS (n=16)).
Supplementary Table 3: Mean utility estimates for the EQ-5D-5L (participants
aged 11+ years) (based on available data)
NB-UVB only
(n=148)
TCS only (n=155) Mean difference
(95% CI)
Mean Std dev Mean Std dev
























TCS only (n=155) Mean difference
(95% CI)


























Note: Utility estimates between adults and those participants aged under 18 years were not
significantly different.
Supplementary Table 4: Mean utility estimates for the CHU-9D (participants
aged <18 years) (based on available data)
NB-UVB only
(n=39)
TCS only (n=40) Mean difference
(95% CI)




























TCS only (n=40) Mean difference
(95% CI)









































































*due to the small sample sizes for those aged <18 years of age (31 had complete
cost and QALY data for TCS, 28 NB-UVB and 35 combination treatment) adjusted
analyses would not run.
Supplementary index of definitions:
Terminology Definition
Adjusted analysis An adjusted analysis takes into account differences
in baseline characteristics between treatment
groups that may influence the outcome. In this
study age and location of target patch were
adjusted for.
Bootstrapping Bootstrapping is a non-parametric statistical
technique which draws repeated random samples,
the same size as the original sample, with
replacement from the data. It can be used to help
explore sampling uncertainty surrounding the mean
Incremental Cost Effectiveness Ratios (ICERs).
Cost effectiveness analysis A cost effectiveness analysis compares two or more
treatments in terms or their cost and outcomes,
where outcomes are measured in a natural unit, in
this study treatment success.
Cost Effectiveness
Acceptability Curve (CEAC)
The CEAC shows the probability of each treatment
being cost‐effective for different levels of the cost‐
effectiveness threshold.
Cost utility analysis A cost utility analysis is a special case of cost
effectiveness analysis where the outcomes are
measured in terms of Quality-Adjusted Life Years.
CHU-9D The CHU-9D stands for Child Health Utility – Nine
Dimensions and is an instrument used to elicit
participants health-related quality of life in terms of
utility which is measured on a scale of 0 (death) to 1
(perfect health). The instrument consists of 9
domains (worry, sadness, pain, tiredness,
annoyance, school, sleep, daily routine and
activities), each with 5 response categories that
assess the child’s functioning “today”. A proxy
version is available for children under the age of 7
years and a self-complete version for those aged 7
to 17 years.
Discounted In economic evaluations longer than one year it is
important to take account of when costs and
outcomes occur this is done by discounting costs
and benefits that occur in the future. This is done to
reflect the fact that people generally value future
costs and outcomes less than current costs and
outcomes.
Economic evaluation An economic evaluation is a form of analysis that
compares two or more interventions in terms of both
their costs and outcomes. In this study we
undertake a cost effectiveness analysis in the
primary analysis and cost utility analyses as
secondary analysis.
EQ-5D-5L The EQ-5D-5L stands for EuroQol five dimensions
with five levels and is an instrument used to elicit
participants health-related quality of life in terms of
utility which is measured on a scale of 0 (death) to 1





These terms refer to the difference in cost between




In this study this is the incremental cost
effectiveness ratio (ICER) which is derived by
dividing the incremental cost by the incremental
benefit, where incremental benefit in this study is
the risk difference.
Multiple Imputation Multiple imputation is a statistical method for
dealing with missing data.
Primary analysis In this study we use the term primary analysis to
refer to the main or base-case analysis which is the
cost effectiveness analyses.
Quality-Adjusted Life Year A quality-adjusted life year combines morbidity and
mortality into a single number where 1 is a year of
perfect health. This is equivalent to 1 QALY
distributed as 0.5 QALY in each of two years (i.e.




The risk difference in this study is the difference
between the observed risks (proportions of
individuals experiencing a treatment success) in the
two treatment groups being compared.
Secondary analysis In this study we use the term secondary analysis to
refer to cost utility analyses. Less weight is placed
on the secondary analysis because of the ceiling
effect found on the EQ-5D-5L.
Sensitivity analysis A number of factors (e.g. how missing data is dealt
with, the unit costs attached to intervention
resources, perspective taken etc) can impact on
estimates of cost-effectiveness. To explore the
impact of these factors on estimates of the
incremental cost effectiveness ratio sensitivity
analysis is undertaken. If changing any of the
factors shifts the conclusions reached it highlights
that the factor is a key determinant and decision
makers ought to consider the role played by that
factor in the analysis and in reaching a decision. If
changing a factor doesn’t change the conclusion
reached that is reassuring and suggests there is
less uncertainty around the results.
Willingness-to-pay An incremental cost effectiveness ratio (in this study
the incremental cost per treatment success)
indicates how much it costs to gain one additional
treatment success for one patient. Decision makers
responsible for making decisions about what to fund
in the NHS will have to decide how much they are
willing to pay for one additional treatment success –
if their willingness-to-pay is higher than the
incremental cost effectiveness ratio then the
intervention can be considered cost effective if it is
lower then the intervention would not be considered
cost effective.
